South Korea · Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 43.27 billion. The enterprise value is 29.80 billion.
| Market Cap | 43.27B |
| Enterprise Value | 29.80B |
Important Dates
The last earnings date was Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Wonbiogen has 7.09 million shares outstanding. The number of shares has decreased by -6.95% in one year.
| Current Share Class | 7.09M |
| Shares Outstanding | 7.09M |
| Shares Change (YoY) | -6.95% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 32.43% |
| Owned by Institutions (%) | n/a |
| Float | 4.79M |
Valuation Ratios
The trailing PE ratio is 6.56.
| PE Ratio | 6.56 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | 6.09 |
| P/OCF Ratio | 4.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.31, with an EV/FCF ratio of 4.19.
| EV / Earnings | 4.50 |
| EV / Sales | 0.87 |
| EV / EBITDA | 3.31 |
| EV / EBIT | 4.00 |
| EV / FCF | 4.19 |
Financial Position
The company has a current ratio of 5.98, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.98 |
| Quick Ratio | 4.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.08 |
| Interest Coverage | 162.41 |
Financial Efficiency
Return on equity (ROE) is 16.17% and return on invested capital (ROIC) is 10.96%.
| Return on Equity (ROE) | 16.17% |
| Return on Assets (ROA) | 10.11% |
| Return on Invested Capital (ROIC) | 10.96% |
| Return on Capital Employed (ROCE) | 17.73% |
| Revenue Per Employee | 446.51M |
| Profits Per Employee | 85.94M |
| Employee Count | 77 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 2.80 |
Taxes
In the past 12 months, Wonbiogen has paid 1.12 billion in taxes.
| Income Tax | 1.12B |
| Effective Tax Rate | 15.22% |
Stock Price Statistics
The stock price has increased by +8.72% in the last 52 weeks. The beta is 0.54, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +8.72% |
| 50-Day Moving Average | 5,432.10 |
| 200-Day Moving Average | 5,496.33 |
| Relative Strength Index (RSI) | 67.62 |
| Average Volume (20 Days) | 56,455 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 34.38 billion and earned 6.62 billion in profits. Earnings per share was 930.43.
| Revenue | 34.38B |
| Gross Profit | 16.60B |
| Operating Income | 7.41B |
| Pretax Income | 7.38B |
| Net Income | 6.62B |
| EBITDA | 8.96B |
| EBIT | 7.41B |
| Earnings Per Share (EPS) | 930.43 |
Balance Sheet
The company has 14.02 billion in cash and 596.72 million in debt, giving a net cash position of 13.42 billion or 1,891.77 per share.
| Cash & Cash Equivalents | 14.02B |
| Total Debt | 596.72M |
| Net Cash | 13.42B |
| Net Cash Per Share | 1,891.77 |
| Equity (Book Value) | 41.47B |
| Book Value Per Share | 5,852.84 |
| Working Capital | 21.25B |
Cash Flow
In the last 12 months, operating cash flow was 8.83 billion and capital expenditures -1.72 billion, giving a free cash flow of 7.11 billion.
| Operating Cash Flow | 8.83B |
| Capital Expenditures | -1.72B |
| Free Cash Flow | 7.11B |
| FCF Per Share | 1,002.33 |
Margins
Gross margin is 48.29%, with operating and profit margins of 21.56% and 19.25%.
| Gross Margin | 48.29% |
| Operating Margin | 21.56% |
| Pretax Margin | 21.46% |
| Profit Margin | 19.25% |
| EBITDA Margin | 26.07% |
| EBIT Margin | 21.56% |
| FCF Margin | 20.68% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.58%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.58% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.72% |
| Buyback Yield | 6.95% |
| Shareholder Yield | 8.53% |
| Earnings Yield | 15.29% |
| FCF Yield | 16.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 8.09 and a Piotroski F-Score of 6.
| Altman Z-Score | 8.09 |
| Piotroski F-Score | 6 |